These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 14697480)

  • 1. CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia.
    Kajinami K; Brousseau ME; Ordovas JM; Schaefer EJ
    Am J Cardiol; 2004 Jan; 93(1):104-7. PubMed ID: 14697480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin.
    Cerda A; Genvigir FD; Arazi SS; Hirata MH; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
    Clin Chim Acta; 2010 May; 411(9-10):631-7. PubMed ID: 20064494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
    Davidson M; Ma P; Stein EA; Gotto AM; Raza A; Chitra R; Hutchinson H
    Am J Cardiol; 2002 Feb; 89(3):268-75. PubMed ID: 11809427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of atorvastatin of the treatment of hypercholesterolemia after renal transplantation.
    Alvarez ML; Errasti P; Gómez G; Lavilla FJ; García N; Ballester B; García I; Purroy A
    Transplant Proc; 1999 Sep; 31(6):2328-9. PubMed ID: 10500602
    [No Abstract]   [Full Text] [Related]  

  • 5. Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia.
    Andrén L; Andreasson A; Eggertsen R
    Eur J Clin Pharmacol; 2007 Oct; 63(10):913-6. PubMed ID: 17701167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.
    Shabana MF; Mishriki AA; Issac MS; Bakhoum SW
    Mol Diagn Ther; 2013 Oct; 17(5):299-309. PubMed ID: 23677857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
    Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK
    DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern.
    O'Keefe JH; Captain BK; Jones PG; Harris WS
    Prev Cardiol; 2004; 7(4):154-60. PubMed ID: 15539961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia.
    Hunninghake D; Insull W; Knopp R; Davidson M; Lohrbauer L; Jones P; Kafonek S
    Am J Cardiol; 2001 Sep; 88(6):635-9. PubMed ID: 11564386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Disturbances in cholesterol metabolism].
    Marschall HU
    Dtsch Med Wochenschr; 2001 Jan; 126(3):63-4. PubMed ID: 11205483
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of simvastatin and atorvastatin in hypercholesterolemic patients.
    Bolaman Z; Kadikoylu G
    Clin Ther; 2003 Oct; 25(10):2631-3. PubMed ID: 14667963
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia.
    Rosales A; Alvear M; Cuevas A; Saavedra N; Zambrano T; Salazar LA
    Clin Chim Acta; 2012 Feb; 413(3-4):495-501. PubMed ID: 22120734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.
    Dart A; Jerums G; Nicholson G; d'Emden M; Hamilton-Craig I; Tallis G; Best J; West M; Sullivan D; Bracs P; Black D
    Am J Cardiol; 1997 Jul; 80(1):39-44. PubMed ID: 9205017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of atorvastatin and atorvastatin withdrawal on soluble CD40L and adipocytokines in patients with hypercholesterolaemia.
    Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
    Acta Cardiol; 2006 Jun; 61(3):263-9. PubMed ID: 16869445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients.
    Willrich MA; Rodrigues AC; Cerda A; Genvigir FD; Arazi SS; Dorea EL; Bernik MM; Bertolami MC; Faludi A; Largura A; Baudhuin LM; Bryant SC; Hirata MH; Hirata RD
    Clin Chim Acta; 2013 Jun; 421():157-63. PubMed ID: 23501331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease.
    Schneck DW; Knopp RH; Ballantyne CM; McPherson R; Chitra RR; Simonson SG
    Am J Cardiol; 2003 Jan; 91(1):33-41. PubMed ID: 12505568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects.
    Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JA; Seman LJ; Ferrari A; Rubenstein JJ
    Am J Cardiol; 2002 Oct; 90(7):689-96. PubMed ID: 12356379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.